Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
81 hedge funds and large institutions have $606M invested in Y-mAbs Therapeutics in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 9 reducing their positions, and 7 closing their positions.
322% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 9
300% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 7
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
77% more capital invested
Capital invested by funds: $342M → $606M (+$264M)
25% more funds holding
Funds holding: 65 → 81 (+16)
10.41% more ownership
Funds ownership: 38.43% → 48.84% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$60.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$21.3M |
| 3 |
BlackRock
New York
|
+$20.4M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.66M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.97M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$2.61M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Canada Life
Winnipeg,
Manitoba, Canada
| $45K | +$42.7K | +1,443 | New |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| $19K | +$18.3K | +619 | New |
|
|
TRCT
78
Tower Research Capital (TRC)
New York
| $17K | +$16.3K | +552 | New |
|
79
Daiwa Securities Group
Tokyo,
Japan
| $7K | +$6.63K | +224 | New |
|
80
UBS Group
Zurich,
Switzerland
| $6K | -$461K | -15,583 | -99% |
|
81
Rockefeller Capital Management
New York
| $5K | – | – | – |
|
|
82
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$21.8M | -837,800 | Closed |
|
|
83
Stifel Financial
St. Louis,
Missouri
| – | -$2.61M | -100,000 | Closed |
|
|
AA
84
ALPS Advisors
Denver,
Colorado
| – | -$1.78M | -68,175 | Closed |
|
85
TD Asset Management
Toronto,
Ontario, Canada
| – | -$697K | -26,753 | Closed |
|
|
TCM
86
Tuttle Capital Management
Riverside,
Connecticut
| – | -$309K | -11,618 | Closed |
|
87
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$234K | -8,974 | Closed |
|
88
Marshall Wace
London,
United Kingdom
| – | -$29K | -1,100 | Closed |
|
YMAB Hedge Fund Activity: Q4 2019 in Review
81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2019, worth a combined $606M — up 77% from $342M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new YMAB positions and 7 closed out — a net gain of 21 holders — while 38 added to existing stakes and 9 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $60.5M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $21.8M sold.
- 81 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2019, up from 65 in Q3 2019.
- Funds reported $606M of Y-mAbs Therapeutics stock for Q4 2019, up 77% quarter-over-quarter.
- 28 funds opened new Y-mAbs Therapeutics positions in Q4 2019 and 7 closed out, a net change of +21 holders.
- The largest Y-mAbs Therapeutics buyer in Q4 2019 was Wellington Management Group, an estimated $60.5M added.
- The largest Y-mAbs Therapeutics seller in Q4 2019 was T. Rowe Price Associates, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2019.